Retrospective evaluation shows improved survival in peritoneal cancer with cytoreductive surgery and HIPEC, indicating a promising treatment approach.
This study analyzes the therapeutic efficacy, survival rates, and complication profiles of CRS plus HIPEC in patients suffering from diffuse peritoneal surface malignancies. A retrospective evaluation of patients undergoing this multimodal strategy demonstrated that a low Peritoneal Cancer Index (PCI) and complete cytoreduction (CC-0) are crucial indicators of prolonged overall survival. Despite considerable hematological and gastrointestinal toxicities, the regional dose intensification and thermal enhancement of cytotoxicity offer a substantial survival advantage compared to conventional systemic chemotherapy alone.
No takes yet. Share an insight, caveat, or question.
Sulaymanov D.A. - PhD (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: